Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up - Sorbonne Université Access content directly
Journal Articles Journal of the American Society of Nephrology Year : 2017

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up

Karine Dahan
  • Function : Correspondent author
  • PersonId : 1004108

Connectez-vous pour contacter l'auteur
Marine Cachanado
Fabrice Mihout
  • Function : Author
Marie Matignon
Tabassome Simon

Abstract

Randomized trials of rituximab in primary membranous nephropathy (PMN) have not been conducted. We undertook a multicenter, randomized, controlled trial at 31 French hospitals (NCT01508468). Patients with biopsy-proven PMN and nephrotic syndrome after 6 months of nonimmunosuppressive antiproteinuric treatment (NIAT) were randomly assigned to 6-month therapy with NIAT and 375 mg/m2 intravenous rituximab on days 1 and 8 (n=37) or NIAT alone (n=38). Median times to last follow-up were 17.0 (interquartile range, 12.5–24.0) months and 17.0 (interquartile range, 13.0–23.0) months in NIAT-rituximab and NIAT groups, respectively. Primary outcome was a combined end point of complete or partial remission of proteinuria at 6 months. At month 6, 13 (35.1%; 95% confidence interval [95% CI], 19.7 to 50.5) patients in the NIAT-rituximab group and eight (21.1%; 95% CI, 8.1 to 34.0) patients in the NIAT group achieved remission (P=0.21). Rates of antiphospholipase A2 receptor antibody (anti–PLA2R-Ab) depletion in NIAT-rituximab and NIAT groups were 14 of 25 (56%) and one of 23 (4.3%) patients at month 3 (P<0.001) and 13 of 26 (50%) and three of 25 (12%) patients at month 6 (P=0.004), respectively. Eight serious adverse events occurred in each group. During the observational phase, remission rates before change of assigned treatment were 24 of 37 (64.9%) and 13 of 38 (34.2%) patients in NIAT-rituximab and NIAT groups, respectively (P<0.01). Positive effect of rituximab on proteinuria remission occurred after 6 months. These data suggest that PLA2R-Ab levels are early markers of rituximab effect and that addition of rituximab to NIAT does not affect safety.
Fichier principal
Vignette du fichier
Dahan_2017_Rituximab_for.pdf (1008.31 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-01490466 , version 1 (15-03-2017)

Identifiers

Cite

Karine Dahan, Hanna Debiec, Emmanuelle Plaisier, Marine Cachanado, Alexandra Rousseau, et al.. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. Journal of the American Society of Nephrology, 2017, 28 (1), pp.348-358. ⟨10.1681/ASN.2016040449⟩. ⟨hal-01490466⟩
486 View
682 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More